CRISPR Therapeutics announced a strategic collaboration with Sirius Therapeutics to co-develop and co-commercialize novel small interfering RNA (siRNA) therapies for thromboembolic disorders and other serious diseases. The lead program under this partnership is SRSD107, a next-generation, long-acting Factor XI (FXI) siRNA. This collaboration diversifies CRISPR Therapeutics' technological platform, complementing its existing gene-editing efforts.
Under the terms of the agreement, CRISPR Therapeutics will make an upfront payment of $95 million to Sirius Therapeutics. The companies will share costs and profits equally for SRSD107, with CRISPR Therapeutics leading commercialization in the U.S. and Sirius leading in Greater China. This financial commitment and shared commercialization strategy underscore the potential value seen in the siRNA platform.
Phase 1 clinical trial data for SRSD107 demonstrated compelling results, including peak reductions in FXI activity exceeding 93% and more than a twofold increase in activated partial thromboplastin time (aPTT). These effects were maintained for up to six months post-dosing, indicating durable efficacy and a well-tolerated safety profile. The collaboration also provides CRISPR Therapeutics with an option to license up to two additional siRNA programs, further expanding its pipeline potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.